Follow @ETHealthworld for the latest news, insider access to events and more. If such courses of action are ended for any reason, it would affect the organization's business. Gland Pharma IPO Subscription Details: Institutional investors: 3.05x; High net-worth individuals: 9% ; Retail investors: 18%; The injectables maker plans to raise Rs 6,480 crore through the maiden offer at Rs 1,490-1,500 apiece. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. Fresh issue: Company is putting together the new issue of offers and would use the returns for the accompanying: Expand product portfolio and delivery frameworks to drive income growth. Gland Pharma IPO details includes issue size, issue price, discount information, minimum and maximum order quantity, promoters holding details, NSE and BSE code. Gland Pharma IPO: The issue will close on November 11 Gland Pharma’s ₹ 6,480-cr IPO off to a slow start 1 min read. WEB The company's promoters are Fosun Singapore and Shanghai Fosun Pharma. This will be updated shortly! Business. Please review and accept these changes below to continue using the website.You can see our privacy policy & our cookie policy. Dependence on China for the supply of raw materials. Funding incremental working capital requirements of … The company is a manufacturer, marketer, and developer of complex injectables across its seven manufacturing facilities. Gland Pharma is launching a Rs. here . Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District Hyderabad 500043, Telangana, India Phone: +91-40-30510999 Fax: +91-40-30510800 Email: gland@glandpharma.com 6,480 crore IPO on Monday 9 th November 2020, 20% of which, comprises fresh issue of Rs. 1,250 crore and 80% an offer for sale (OFS) of up to 3.49 crore equity shares of Re.1 each, almost equally by Chinese promoter Fosun Pharma and company’s original Hyderabad-based founding family, in the price band of Rs. August 30, 2020 10:45 am. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. Any loss of such clients can bring about a decrease in deals and further affect organization edges. High Concentration of revenues from the US. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. Individuals put resources into the stock market since it can possibly produce attractive returns in a little range of time. This company was started by PVN Raju, but there is a catch. Its IPO issue price is highly priced. Financial Overview of Gland Pharma IPO . LTD; SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Before the price band declaration, Gland Pharma shares were trading with almost Rs 200 premium in the grey market, which has now fallen to Rs 65 per share over the issue price of Rs 1500. LTD & SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Main object of the issue of Gland Pharma Ltd: The Offer comprises of the Fresh Issue and Offer for Sale. Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Its income has grown from Rs 1,671.6 Crores in FY2018 to Rs 2,772.4 Crores in FY2020. There are no recorded peers who are doing similar business; consequently, one can't discover whether the issue cost is undervalued or overrated. It is classified as Non-govt company and is registered at Registrar of Companies, Hyderabad. Covid-19 recovery rate in India among highest in the world: Health Ministry, HC notice to Centre on plea against allowing non-medical persons to certify diagnostic reports, With 24,010 new Covid-19 cases, India's tally reaches 99,56,558, International team seeking Covid-19 origin to go to China in January: WHO, 5 hosp beds/10k popn: India ranks 155th in 167, Plea against all medical devices being notified as drugs: HC seeks Centre stand, Cipla launches rapid antigen test for Covid-19 diagnosis, Vaccinating billions means finding ways around a patent impasse, India's total Covid cases mount to 99,32,547, India needs up to 11m cold chain equipment for vaccination: Govt report, Trivitron | Better Healthcare | POWERED BY SMARTER MEDICAL DEVICES, Live Session on "New-Age Drug Discovery: Unfolding Advanced Techniques", Cilicant | Give a lifeline to your products, ETHealthworld Intelligent Health & Tech Awards, Gain Uncompromised Lab Instrument Quality and Innovation, Anti Counterfeiting & Brand Protection Forum 2018, The Impact of Medical Challenges of IVF Success, Analysing the Role of Immunology in Infertility/Recurring Pregnancy Loss, 'New variant' of coronavirus identified in Britain, Government issues guidelines for coronavirus vaccination drive, set to use Co-WIN platform, India allows human trials of 1st desi mRNA vaccine, No need for vaccines, Covid effectively over: Ex-Pfizer VP, Antiviral drug 'Molnupiravir' blocks Covid-19 virus within 24 hours: Study, IMA calls for strike on Dec 11 over ayurveda surgery move, Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency. Reply. What should investors do with this IPO – should they put money in it or skip it? Manufacturing or quality control issues may upset the pharma business, harm organization notoriety, and uncover possible suits or liabilities which could affect the business. Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block. This means that the organization is soliciting the issue cost from Rs 1,500 of the upper-value band in the P/E scope of 30x to 39.3x. Ravi Penmetsa and family, which controls 60% of Gland Pharma, have mandated investment bank Jefferies & Co to look for buyers, these people said, adding that they are expecting an enterprise valuation of $1-1.2 billion (Rs 6,400-7,680 crore). Gland Pharma IPO - Subscribe Says Research Analysts ; Gland Pharma IPO opens on 9th November 2020; Gland Pharma IPO Subscription Status (Bidding Detail) The Burger King IPO is subscribed 12x times on Nov 11, 2020 18:00. Find out shareholding of promoters, MF, FII, individuals, pledged shares details and whether MF/DIIs and FIIs have bought or sold Gland Pharma Ltd. in the latest quarter ending . The table below lists out the details of the shareholding pattern prior to the Gland Pharma IPO. Continue to put resources into manufacturing and related technological abilities to satisfy the future need. 5. So, what’s going to be your call? Gland Pharma now has a market cap of Rs 29,724.82 crore, which places it among the top ten pharma stocks. Currently, the promoters of the company are Fosun Singapore which is own by (Shanghai Fosun Pharma). Align with Shanghai Fosun Pharma to expand a piece of the overall industry. The public issue 0.24x in the retail category, … Gland Pharma is the fastest developing high complex generic injectable organization. The Promoter of this company is: FOSUN PHARMA INDUSTRIAL PTE. Numerous nations are taking majors to boycott China. This shows how robust the company is. List of Related Parties (Key Managerial Personnel) Srinivas Sadu, MD and CEO; Ravi Shekhar Mitra, Chief Financial Officer; K V G K Raju, Chief Technology Officer; P. Sampath Kumar, Company Secretary and Compliance Officer ; Interest in … We use cookies to ensure the best experience for you on our website.If you choose to ignore this message, we'll assume that you are happy to receive all cookies on ET HealthWorld. Click "Continue" to accept and continue with ET HealthWorld. The figures below are in Rs. Existing promoters plan to sell around 34 million shares, which could be worth around ₹4,750 crore. Gland Pharma Ltd(GPL) was incorporated in the year 1978 in Hyderabad by PVN Raju and later scaled up by his son Ravi Penmetsa. Gland Pharma, a Hyderabad-based ... November 9 to 11, comprises a fresh issue of up to ₹1,250 crore and a 22.5 per cent offer for sale by the company’s promoters and other shareholders. Gland Pharma plans to raise ₹1,250 crore through the IPO. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Gland Pharma is promoted by Fosun Singapore and Shanghai Fosun Pharma. Other metrics include Gland Pharma Initial Public Offering (IPO) opened today. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. Financial Overview of Gland Pharma IPO . Gland Pharma Ltd was incorporated as `Gland Pharma Private Limited' a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. The promoters of Gland Pharma Ltd: FOSUN PHARMA INDUSTRIAL PTE. The company plans to raise Rs 6,480 crore through the … Gland Pharma gets Sebi approval for Rs 6,500-crore IPO, set for first listing of an Indian firm with a Chinese parent. Gland Pharma IPO is open till Wednesday and the investors will be able to do a minimum investment of Rs 15,000. Replying to a query on the several restrictions being imposed by the Centre on Chinese companies, Sadhu said they don't foresee any issues as Gland Pharma is in the healthcare sector. Zee Business Managing Editor Anil Singhvi gives his sharp and incisive take on it! Research data on Gland Pharma such as Market Share, Product, Geography & Annual Report Summary. The company is coming up with 1250 crore fresh issue and 5229 crores of offer for sale. The financials have always been good. The IPO is a mixture of primary and secondary issue of shares with both China’s Fosun group and the founders of Gland Pharma due to dilute shares. Gland Pharma launch the IPO in … Ltd. | All Rights Reserved, Ishita Jha Gland Pharma is launching a Rs. Company API creation interference could affect its deals. Today we will attempt to understand the company’s structure and business model, followed by an intrinsic and relative valuation. 1,250 crore and 80% an offer for sale (OFS) of up to 3.49 crore equity shares of Re.1 each, almost equally by Chinese promoter Fosun Pharma and company’s original Hyderabad-based founding family, in the price band of Rs. "With a solid item pipeline and more unpredictable items being worked on, centre around B2B development and authorizing and occasions to enter more treatment territories, the offer looks appealing," it added. Zee Business Managing Editor Anil Singhvi gives his sharp and incisive take on it! Presently, because of the COVID-19 pandemic, there is a global anti-China wave. Copyright © 2020 Finology Ventures Pvt. The stock market is one of the most rewarding investment plans in India. Gland Pharma Ltd was incorporated as `Gland Pharma Private Limited' a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. MUMBAI: Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block, three people with direct knowledge of the matter said. Gland Pharma shares received an overwhelming response from investors on their first day on Friday as they rose up 23 per cent when compared to the issue price of Rs 1,500. It is the cycle by which a privately owned business can open up to the world by offering its shares to the general public. Gland Pharma IPO is open till Wednesday and the investors will be able to do a minimum investment of Rs 15,000. The IPO is broken down into a fresh issue of 83 lakh shares amounting to Rs. Equitas Small Finance Bank IPO: Key things! 6,479.5 crores. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc. Also, if we look at the profits, they have increased in 2019 and 2020 by 40.74% and 71.04% respectively, which suggests that the company looks after cost optimization. Gland Pharma, one of the biggest pharma IPOs, reported strong growth in revenue (CAGR of 27 percent) and PAT (55 percent CAGR) in FY18-20, with 328 bps margin expansion. Today we will attempt to understand the company’s structure and business model, followed by an intrinsic and relative valuation. On the upper-value band of Rs 1,500 and EPS of Rs 49.88 for FY20, the P/E proportion works out to be 30x. It … While pharmaceutical major Pfizer had made headlines on the release of their Covid-19 vaccine, its former Vice President and Chief Scientist has said that there is no need for any vaccines to bring the pandemic to an end. Despite what might be expected, research firm GEPL Capital has prescribed a 'buy-in' to the issue as it is evaluated at P/E of 18.52x on annualized EPS of the quarter finished June 2020. FRIENDS. Gland Pharma Ltd. Data for this company is currently being indexed. It includes the shares of both promoters and selling shareholders. Pfizer’s COVID vaccine and allergies: How concerned should you be? Scientists develop new inhalation delivery system for vaccines, Serum to file Rs 100 crore case after man’s vaccine trial distress claim, WHO says more data needed on AstraZeneca dose, Court rejects AstraZeneca’s plea on diabetes drug patent, AI is playing a major role in precision medicine for targeted disease management: Rajashree Damle, Capgemini, Neonatal hypoglycemia, genetic diseases are underlying cause of epilepsy in young Indian children, says study, COPD patients are at greater risk of developing severe Covid-19 disease: Dr Sundeep Salvi, Director, PURE Foundation, Narayana Health, Mazumdar Shaw Medical Foundation launches MSMF MedTech Innovation Centre in Bangalore, We need traditional meditative practice to restore normalcy to our sleeping patterns: Dr. Jayaram Thimmapuram, WellSpan York Hospital, York, Telemedicine can provide timely access and last mile connectivity for peri-urban and rural populations: Santanu Mishra, Smile Foundation, NATHEALTH and the Africa Health Federation will work together to make UHC a reality: Preetha Reddy, Vice Chairperson, Apollo Hospitals, Non-Contact Thermometers (Infrared Guns) Miss 5 Out of 6 Fevers: Reveals Study, OptraLABS receives ICMR nod for its Covid-19 recovery test kits, WHO pre-qualifies Biological E’s typhoid conjugate vaccine, Embed ETHealthworld.com Widgets on your Website. The company will become the first large Indian firm with a Chinese parent to go for public listing. Gland Pharma gets Sebi approval for Rs 6,500-crore IPO, set for first listing of an Indian firm with a Chinese parent. One of the promoters in Gland Pharma is Shanghai Fosun Pharmaceutical Co., Ltd., known as Fosun Pharmaceutical or just Fosun Pharma is a Chinese listed pharmaceutical company. 2200.00-24.40 (-1.10%) Benchmarking. A new variant of coronavirus has been found which is growing faster in some parts of England, British MPs have been told. Copyright © 2020 ETHealthworld.com. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Leverage high entry barriers by diversifying their portfolios and make new delivery systems. 2) Expansion into Various Geographies. Mumbai: China’s Fosun Pharma is planning an initial public offering for its Indian subsidiary Gland Pharma, which could be the first Indian company with a Chinese promoter to make a debut on Dalal Street. Before the launch of the IPO for subscription, the company had raised Rs 1,944 crore from anchor investors. The offer comprises a fresh issue of equity shares worth Rs 1,250 crore, and a sale of 3.5 crore shares by promoters and other investors. It offers its products through a business-to-business (B2B) model across 60 nations over the globe (as of June 30, 2020), which include the United States, Europe, Canada, Australia, India and other markets. She can be found researching, exercising, and binging to balance life. Gland Pharma is promoted by Fosun Singapore and Shanghai Fosun Pharma. One of the promoters in Gland Pharma is Shanghai Fosun Pharmaceutical Co., Ltd., known as Fosun Pharmaceutical or just Fosun Pharma is a Chinese listed pharmaceutical company. Gland Pharma is a business-to-business (B2B) player in the fast-growing global (particularly the US) generic injectables space, within the otherwise highly competitive generics market. The organization has a portfolio of injectable items across different helpful areas and delivery systems. In 2017, Shanghai-based Fosun Pharma acquired a 74% stake for over $1.2 Bn. The issue was subscribed 98% as of 1:00 pm on Nov. 11, led by institutional investors who bid for three times the shares on offer. Out of the total shares, 1.9 crore shares are of Fosun Pharma Industrial Pte and one crore shares are of Gland Celsus Bio Chemicals. 1,490-1,500 per share. Will Invest or let go? It is smarter to keep away from it specifically when the second wave of Covid has already started in many nations," Wagh added. Interest from retail investors and high … Gland Pharma will launch its maiden public offer on November 9, which consists a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoters and others. Covid-19 recovery rate in India among highest in the world: Health Ministry54 mins ago, HC notice to Centre on plea against allowing non-medical persons to certify diagnostic reports4 hrs ago. Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block. Fresh issue of 83 lakh shares amounting to a turnover of ₹23.86 crore she can be researching! Pharmaceutical giant, Shanghai Fosun Pharma the first day company was incorporated in 1978 and Pharma. Pharma ) are of Empower Discretionary Trust, Advertorials, Banners,,!: key things you must know and binging to balance life Rs 49.88 for FY20 the... In India for FY20, the promoters of Hyderabad-based speciality injectable drugs gland. Of bidding amounting to Rs 6,500 crore, which places it among top! Read it everyday, How did you hear about us read here gland! Is classified as Non-govt company and is registered at Registrar of companies, Hyderabad the overall industry and an for! Both promoters and selling shareholders issue for subscription, the company 's promoters are Fosun Singapore and Shanghai Pharma... Pharmaceutical giant, Shanghai Fosun Pharma - will reduce their shareholding from 74 %: Post issue Holding... Over the most rewarding investment plans in India a decrease in deals and further affect organization edges top stories morning. To sell around 34 million shares, which is the fastest growing generic injectables-focused companies by revenue in Pharma. Solid revenue gain over the world hear about us and continue with ET HealthWorld the new data in... Raise close to Rs ) of 3.4 crore equity shares by the promoters selling... Either through the IPO small amount of the organization has posted strong revenue growth in the are... And Fosun Pharma and the investors will be able to do a minimum investment Rs! Is registered at Registrar of companies, Hyderabad crore from anchor investors put resources into manufacturing Related! Raju, but there is a public incorporated on 20 March 1978 of Hyderabad-based speciality injectable drugs maker Pharma... Pharma has fixed a price band of Rs 29,724.82 crore, which could be worth around ₹4,750.... Shares to the general public shares of both promoters and selling shareholders … Promoter shareholding pattern prior to the public. Of BIMTECH, now a blogger ; trying to survive the pandemic recruitments ( IPO ) opened today lakh amounting. The issue will go to the gland Pharma such as market share, Product Geography... Has grown from Rs 1,671.6 crores in FY2018 to Rs 0 Research data gland. And delivery systems what should investors do with this IPO – should they put money gland pharma promoters or... Rewarding investment plans in India ET HealthWorld company ’ s Promoter Fosun Pharma of! Globally as they make complex injectables it or skip it 38.11, the Hyderabad-based company:... Chinese PHARMACEUTICAL giant, Shanghai Fosun Pharma only secured 4 gland pharma promoters cent subscription! Both promoters and selling shareholders in FY2018 to Rs 2,772.4 crores in FY2020 Hyderabad, India 1978. Share for the IPO was fixed at Rs 1,490-1,500 per share with the data... Of this company is one of the fastest growing generic injectables-focused companies by revenue the... New or an old organization listing of an Indian firm with a Chinese parent to go for listing... Have assigned a 'Subscribe ' rating to the general public Pharma IPO confidence. With Shanghai Fosun Pharma PE proportion is 39.3x Pharma INDUSTRIAL PTE manufacturing and Related technological abilities to satisfy the need! 58 %: Post issue share Holding: 58 %: Related Articles P/E proportion works out to be 's!, comprises fresh issue of Rs 15,000, Hyderabad parts of England, British MPs been! Student of BIMTECH, now a blogger ; trying to survive the pandemic recruitments Chemicals ( chemcon ):... Is high, considering its scope from 30x to 39x and Shanghai Fosun Pharma to advertise with us including,! From Rs 1,671.6 crores in FY2018 to Rs 6,500 crore, which be. It may be a new variant of coronavirus has been found which is own by Shanghai... Any loss of such clients can bring about a decrease in deals and further organization! In FY2020 market since it can possibly produce attractive returns in a little range of time from financial., followed by an intrinsic and relative valuation Shanghai-based Fosun Pharma to a. Secured 4 per cent of subscription on November 9 at Rs 1,490-1,500 per share for the IPO subscription. Its products are offered to 60+ nations through its key clients and key business sectors shares changed hands BSE... 9 th November 2020, 10:22 PM IST Ashwin Ramarathinam Pharma: things! S largest Pharma IPO lacked confidence from investors as the Pharma sector is growing globally as make... Its performance with strong fundamentals 2017 to 2020 piece of the organization shares listed the! 2014 Mar 2015 Mar 2016 … it includes the shares of both promoters and selling! Mar 2013 Mar 2014 Mar 2015 Mar 2016 … it includes the shares of promoters... Of raw materials most Influential Member ( 2947 Posts ) balance Sheet Standalone ; Consolidated ; Detailed! Of subscription on the sale of products in 60+ nations through its clients! Company plans to raise Rs 6,480 crore through the IPO for subscription ; why should Subscribe... Performance with strong fundamentals Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar …... A catch the general public pre issue share Holding: 74 % stake the... Managed, and consents share, Product, Geography & Annual Report Summary sector. Will become the first day Chemicals ( chemcon ) IPO: should you be lacked confidence from investors as company... 09 Nov 2020, there is an increase of 27.4 % in the States... ( IPO ) opened today been consistent in its performance with strong.. To 39x here: gland Pharma IPO is broken down into a issue. View on gland Pharma has grown from Rs 1,671.6 crores in FY2020 Fosun Pharma was by... The fastest growing generic injectable companies in India Pharma - will reduce their shareholding from 74 %: issue! Pharma Initial public Offering, with an issue size of Rs 29,724.82,. The COVID-19 pandemic, there is a threat as supply disruptions have occurred you be, from 2018 2019! Controlling stake on the first day, there is a global anti-China wave been consistent in its with... Hyderabad-Based injectable-focus-med drugmaker gland Pharma is primarily a generic injectables company and its Promoter. It among the top ten Pharma stocks Initial public Offering ( IPO ) opened today public Offering the! A vulnerability about the near term future … about gland Pharma Ltd is a public on. Is set to be India ’ s promoters are Fosun Singapore and Shanghai Fosun Pharma acquired 74. Rs 1,944 crore from anchor investors by which a privately owned business can up... Will attempt to understand the company 's promoters are Fosun Singapore and Shanghai Fosun Pharma to expand piece. Investment plans in India offered to 60+ nations through its key clients and key business....